Depression and anxiety among patients with psoriasis: A correlation with quality of life and associated factors

Bakar, Raishan Shafini; Jaapar, Sharifah Zubaidiah Syed; Azmi, Afiq F.; Aun, Yeoh C.

doi:10.1016/j.jtumed.2021.02.008

Cited by 27 publications

(26 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this study, we found that the prevalence of depression among patients with severely impaired QOL was almost 19%, with a mean score of 6.72 (SD 4.412). A recent study at a similar site using the Hospital Anxiety and Depression Scale (HADS) to assess depression found about 8.5% of patients had depression [ 29 ]. Generally, the proportion of psoriasis patients with depression symptoms ranged from 9% to 55%, likely due to differences in the screening methods and study populations [ 4 ].…”

Section: Discussionmentioning

confidence: 99%

Quality of Life and Its Associated Factors among Patients with Psoriasis in a Semi-Urban Northeast Malaysia

Fuat

Yudin

Muhammad

et al. 2022

IJERPH

View full text Add to dashboard Cite

Psoriasis is a chronic relapsing dermatological disorder that significantly affects the patients’ psychosocial well-being and quality of life (QOL). This study aimed to determine the proportion of severely impaired QOL, the factors associated with severely impaired QOL, and its correlation with depression among semi-urban populations on the Northeast Coast of the Peninsular Malaysia. A cross-sectional study was conducted among 257 patients with psoriasis at the Dermatology Clinic of Hospital Sultanah Bahiyah via a self-administered questionnaire that included sociodemographic profiles, the validated Malay version of the Dermatology Life Quality Index (DLQI), and the Malay version of the Beck depression scale. The data were analysed using logistic and linear regression models. About 20.5% of the patients had severely impaired QOL quality of life, while 79.5% of the patients had non-impaired QOL. Multiple logistic regression analysis showed that the psoriatic severity [Adjusted OR = 1.91, 95% CI: 1.76, 9.93; p < 0.001] and exposed area [Adjusted OR 2.93, 95% CI: 0.38, 2.29; p = 0.050] had a significant association with severely impaired QOL. Among the patients, 18.7% had a positive result in the screening for depression, which revealed a significant association between QOL and depression scores [r = 0.47, 95% CI: 0.35, 0.56, p < 0.001]. Psoriasis can impair QOL and have a relation with mental health. Regular screening for depression among patients with psoriasis is a beneficial strategy for the early detection of depression, especially in semi-urban areas.

show abstract

Section: Discussionmentioning

confidence: 99%

Quality of Life and Its Associated Factors among Patients with Psoriasis in a Semi-Urban Northeast Malaysia

Fuat

Yudin

Muhammad

et al. 2022

IJERPH

View full text Add to dashboard Cite

show abstract

“…In turn, the psychological stress might worsen the severity of psoriasis. A cross-sectional study reported anxiety in approximately 17% of psoriasis patients and a positive correlation with the dermatology life quality index (DLQI) [57]. In this study, an EPM test was performed to evaluate anxiety-like behavior in psoriasis mice and the beneficial effects of coptisine.…”

Section: Discussionmentioning

confidence: 99%

Coptisine Alleviates Imiquimod-Induced Psoriasis-like Skin Lesions and Anxiety-like Behavior in Mice

et al. 2022

View full text Add to dashboard Cite

Psoriasis is a common inflammatory skin disorder, which can be associated with psychological disorders, such as anxiety and depression. This study investigated the efficacy and the mechanism of action of a natural compound coptisine using imiquimod (IMQ)-induced psoriasis mice. Coptisine reduced the severity of psoriasis-like skin lesions, decreased epidermal hyperplasia and the levels of inflammatory cytokines TNF-α, IL-17, and IL-22. Furthermore, coptisine improved IMQ-induced anxiety in mice by increasing the number of entries and time in open arms in the elevated plus maze (EPM) test. Coptisine also lowered the levels of inflammatory cytokines TNF-α and IL-1β in the prefrontal cortex of psoriasis mice. HaCaT keratinocytes and BV2 microglial cells were used to investigate the effects of coptisine in vitro. In M5-treated HaCaT cells, coptisine decreased the production of IL-6, MIP-3α/CCL20, IP-10/CXCL10, and ICAM-1 and suppressed the NF-κB signaling pathway. In LPS-stimulated BV2 cells, coptisine reduced the secretion of TNF-α and IL-1β. These findings suggest that coptisine might be a potential candidate for psoriasis treatment by improving both disease severity and psychological comorbidities.

show abstract

“…A larger study investigating depression and anxiety in psoriasis patients revealed that 8.5% of patients had depressive symptoms and 16.9% had anxiety symptoms, lesions on the lower limbs and dyslipidemia being associated with depression in the studied population. 7 Another study comparing the prevalence of emotional disorders in patients diagnosed with psoriasis revealed that overall, patients with psoriasis were more likely to develop depression compared to the control group, whereas late-onset psoriasis was associated with both anxiety and depression. 8 Overall, the prevalence of psychiatric conditions in psoriasis is suggested to be in the range of 24-90%, with the same authors concluding that psychiatric disorders tend to be underdiagnosed in psoriasis patients.…”

Section: Discussionmentioning

confidence: 99%

Psoriasis-Related Stigma: Is There More to Uncover?

Decean

Badea

Ilieş

et al. 2022

Journal of Interdisciplinary Medicine

View full text Add to dashboard Cite

Background: Psoriasis is a common, inflammatory immune-mediated dermatosis, occurring in patients of all ages, sexes, and races, associating significant comorbidities. One such comorbidity is represented by psychological disorders, which negatively influence the clinical course of the disease. The purpose of our study is to offer a first glimpse into the stigmatization of Romanian psoriasis patients, as well as their potential anxious or depressive manifestations. Materials and methods: The present study is based on an adapted questionnaire previously used to estimate stigmatizing attitudes in the general population, mirrored to reflect the patients’ experience in social situations such as shaking hands, maintaining friendship, kissing, or intercourse. GAD7 and PHQ8 scales were used to screen for anxiety or depression traits in the same patients. Results: Our study group consisted of 12 psoriasis patients, with a mean age of 46.75 years. While few patients reported feeling discriminated against in social contexts, 16.66% presented with mild depressive symptoms recorded by PHQ8 and 24.99% presented mild anxiety manifestations according to their GAD7 scores. Conclusion: In spite of the small sample group, our study outlines a tendency for depressive and anxious manifestations in patients with psoriasis.

show abstract

Depression and anxiety among patients with psoriasis: A correlation with quality of life and associated factors

Cited by 27 publications

References 21 publications

Quality of Life and Its Associated Factors among Patients with Psoriasis in a Semi-Urban Northeast Malaysia

Quality of Life and Its Associated Factors among Patients with Psoriasis in a Semi-Urban Northeast Malaysia

Coptisine Alleviates Imiquimod-Induced Psoriasis-like Skin Lesions and Anxiety-like Behavior in Mice

Psoriasis-Related Stigma: Is There More to Uncover?

Contact Info

Product

Resources

About